TFBS BIOSCIENCE, INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
TFBS provides two main services: One service is the viral vector manufacturing for cell and gene therapy products. With established expertise and effective communication, TFBS has successfully completed several customized viral vector manufacturing projec
The content above was translated by Ai
Founded Year
2016
Unified Business No.
52209120
Status
Active
Number of Employees
65
Total Paid-in
Capital
353,841,610 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2023)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
TFBS Bioscience Inc. was founded in 2016 as the first Contract Research Organization (CRO) providing biological testing in Taiwan. Our technical team's roots run deeper, going back to the virus research laboratory founded in 2009 at the Development Center of Biotechnology (DCB), a government-sponsored research institute in Taiwan. TFBS has established good reputation and track records in several regulatory submissions, winning trust from the international regulatory agencies and biopharmaceutical industry. TFBS has launched the first viral vectors Contract Development and Manufacturing Organization (CDMO) facility in Taiwan, providing fully integrated end-to-end contract development and manufacturing services for the needs of clinical trials. Nowadays, with our manufacturing expertise and state-of-the-art facility, we are determined to be the best partner offering clients a one-stop-shop solution for gene and cell therapy.
The content above was translated by Ai
